{"entity":{"id":"nct07123454","kind":"trial","name":"A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphom","aka":[],"tldr":"A phase 1/2 trial of AZD4512 in hodgkin lymphoma and non-hodgkin lymphoma, run by AstraZeneca, now recruiting.","summary":"A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma is a phase 1/2 interventional study registered as NCT07123454 by AstraZeneca, with 91 participants planned, started 2025-09-24 and due to reach its primary completion in 2028-03-01. Interventions recorded: AZD4512. Conditions listed: B-cell Non-Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07123454","url":"https://clinicaltrials.gov/study/NCT07123454"}],"tags":["ctgov-ingest"],"related":[],"cancers":["hodgkin-lymphoma","non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["azd4512"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07123454","phase":"1/2","setting":"A Modular Phase I/II Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Efficacy of AZD4512 Monotherapy or in Combination With Other Anticancer Agent(s), in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) (Lumi-NHL)","sponsor":"AstraZeneca","participation":[{"nct":"NCT07123454","source":"https://clinicaltrials.gov/study/NCT07123454","fetchedAt":"2026-10-07T16:55:27.525Z","studySha256":"dfc9366c65e2dfba827333ef48f314577ca6c1f1d1ee2319a40027ccaefd9d05","overallStatus":"RECRUITING","lastUpdatePosted":"2026-08-28","leadSponsor":"AstraZeneca","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":91,"enrolmentType":"ESTIMATED","siteCount":23,"recruitingSiteCount":16,"countries":["Australia","China","Italy","Japan","South Korea","Taiwan","United Kingdom","United States"]}],"started":"2025-09-24","startedType":"actual","enrolled":91,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07123454/","neighbours":{"cancer":[{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"drug":[{"id":"azd4512","kind":"drug","name":"AZD4512","route":"/drugs/azd4512/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}